These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Autologous HSCT in systemic sclerosis: a step forward. Farge D; Gluckman E Lancet; 2011 Aug; 378(9790):460-2. PubMed ID: 21777973 [No Abstract] [Full Text] [Related]
24. Therapeutic interventions in systemic sclerosis. van den Hoogen FH Neth J Med; 1998 Sep; 53(3):137-8. PubMed ID: 9803147 [No Abstract] [Full Text] [Related]
25. Treatment of complications associated with systemic sclerosis. Moore SC; Desantis ER Am J Health Syst Pharm; 2008 Feb; 65(4):315-21. PubMed ID: 18238768 [TBL] [Abstract][Full Text] [Related]
26. Use of methotrexate in patients with scleroderma and mixed connective tissue disease. Kowal-Bielecka O; Distler O Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S160-3. PubMed ID: 21044452 [TBL] [Abstract][Full Text] [Related]
27. Therapy of scleroderma renal crisis: State of the art. Zanatta E; Polito P; Favaro M; Larosa M; Marson P; Cozzi F; Doria A Autoimmun Rev; 2018 Sep; 17(9):882-889. PubMed ID: 30005860 [TBL] [Abstract][Full Text] [Related]
29. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature. Zandman-Goddard G; Tweezer-Zaks N; Shoenfeld Y Clin Dev Immunol; 2005 Sep; 12(3):165-73. PubMed ID: 16295521 [TBL] [Abstract][Full Text] [Related]
30. [Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?]. Verrecchia F; Michel L; Keshtmand H; Wang Y; Launay D; Farge D Rev Med Interne; 2009 Nov; 30(11):955-62. PubMed ID: 19349102 [TBL] [Abstract][Full Text] [Related]
31. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Steen VD; Medsger TA Arthritis Rheum; 1998 Sep; 41(9):1613-9. PubMed ID: 9751093 [TBL] [Abstract][Full Text] [Related]
32. Juvenile systemic sclerosis: experience from a tertiary care center from India. Bagri NK; Raj D; Kaur J; Punia H; Saini I; Lodha R; Kabra SK Rheumatol Int; 2017 Oct; 37(10):1687-1691. PubMed ID: 28831595 [TBL] [Abstract][Full Text] [Related]
34. [Evidence-based therapy of systemic sclerosis]. Genth E Z Rheumatol; 2001 Dec; 60(6):464-8. PubMed ID: 11826742 [TBL] [Abstract][Full Text] [Related]
35. The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. Strange G; Nash P Int J Rheum Dis; 2009 Sep; 12(3):192-206. PubMed ID: 20374346 [TBL] [Abstract][Full Text] [Related]
36. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST. Fathi N; Furst DE; Clements PJ Curr Rheumatol Rep; 2007 May; 9(2):144-50. PubMed ID: 17502045 [TBL] [Abstract][Full Text] [Related]
37. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972 [TBL] [Abstract][Full Text] [Related]
38. Scleroderma in children. Zulian F Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):576-595. PubMed ID: 29773274 [TBL] [Abstract][Full Text] [Related]